Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.

Gabriel BstehSophie DürauerHamid AssarHarald HegenBettina HeschlFritz LeutmezerFranziska Di PauliChristiane GradlGerhard TraxlerGudrun ZulehnerPaulus Stefan RommerPeter WipflerMichael GugerRomana HöftbergerChristian EnzingerThomas Berger

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

Humoral immunity is stable after SARS-CoV-2 infection in MS, but is reduced by immunosuppressive DMT, particularly anti-CD20 monoclonal antibodies. This provides important evidence for advising pwMS as well as for planning and prioritizing vaccination.

Keyphrases

immune response
multiple sclerosis
coronavirus disease
sars cov
dendritic cells
mass spectrometry
toll like receptor
ms ms
inflammatory response